Alzheimer’s is an irreversible and progressive brain disorder that destroys memory and thinking skills over time and also affects the ability to perform simple tasks. This is the common cause of dementia responsible for the majority of cases. It affects older adults; you should not consider it a normal part of aging. This disease is determined by two toxic proteins: Tau and A. Amyloid collects in the form of sticky plaques outside the neurons, and Tau in the form of tangled threads inside neurons. Tracking these markers is important because they are linked with the cognitive changes due to Alzheimer’s disease.
Two Proteins Of Alzheimer’s: Amyloid And Tau
Amyloid: In the healthy brain, this protein splits and gets cleared. During Alzheimer’s, these proteins clump and warp together as plaques, interrupting the communication from cell to cell.
Tau: This is the structural support balancing the microtubules that deliver the nutrients inside neurons. In Alzheimer’s disease, tau gets detached from microtubules, becomes hyperphosphorylated and groups together into toxic tangles.
Sequences Of The Amyloid And Tau
Amyloid Buildup: Amyloid starts building up in the brain without showing any signs or symptoms, 15 to 20 years before the first appearance of clinical signs for memory loss. Amyloid causes structural changes in the brain and cognitive changes. Amyloid is viewed as a catalyst that boosts the spread of tau.
Tau Spreading: While amyloid stays enclosed, tau tangles spread in a systematic manner through the brain, moving from the memory centres to the cerebral cortex. The volume and spread of tau very closely correlate with the severity of cognitive impairment of patients, such as memory loss, spatial disorientation and language dysfunction.
Detrimental duo: According to the scientist, if you have early-stage tau and high amyloid, the rate of cognitive changes gets tripled as compared to having one or no biomarker.
How To Track Alzheimer’s With Biomarkers?
Tracking the development of these markers becomes more advanced; for final diagnosis, an autopsy is required. But the biological landscape is dependent on the diagnostic tools for the connection of cognitive behaviour with biology. Those diagnostic tools are mentioned below:-
PET Scans: These are helpful to get a direct image and map the location and volume of tau tangles and amyloid plaques in the brain. These are highly reliable predictors of the stage of the disease and cognitive changes.
Blood-Based Biomarkers: The rapidly evolving and invasive area of blood revolves around blood plasma testing, which particularly measures the biomarker. Increased levels of biomarkers are highly capable of predicting the future risk of cognitive changes years before clinical symptoms emerge.
CSF Tests: These tests allow the doctors to measure the concentration of tau proteins. The high concentration of amyloid to tau is the signal of advanced cognitive decline.
Conclusion
By observing how tau and amyloid makers are responsible for the cognitive changes, researchers are now better equipped to diagnose the disease biologically and treat it well in advance. If you are looking for the diagnostic options and want to understand this risk more, then consulting with the neurologist is the next step. For more guidance, you may consult with Dr. Sukhdeep Singh Jhawar, an esteemed neurologist with more than 15 years of experience. He is extensively trained to perform neurosurgeries with innovative technology. At Dr. Jhawar Neuro Hospital, he always commits to improving the health of patients and takes steps to achieve excellence.
FAQ’S
- Is it possible that plaque and tangles form at the same time?
No, it’s not possible that plaque and tangles form at the same time.
- Which treatments target the plaque and tau tangles?
Amyloid targeting immunotherapy and tau targeting therapies are treatment approaches that target the plaque and tangles.
